Literature DB >> 3158073

[Ciprofloxacine: evaluation of its biliary elimination in man].

J M Brogard, F Jehl, J P Arnaud, P Lévy, F Peladan, J F Blicklé, H Monteil.   

Abstract

To investigate the possibility of therapeutic use of ciprofloxacin in infections of the biliary tract, the serum and bile kinetics, and the biliary, urinary and fecal elimination of this new broad-spectrum quinolone were studied in 12 recently cholecystectomized patients with T-tube drainage. Ciprofloxacin concentrations were determined by simultaneously performed HPLC and microbiological assay in serum, urine, and bile over a 24-hour period following oral administration of a single dose of 500 mg of the drug. The two methods yielded similar values both in the serum and in the urine. Average peak serum concentrations were 0.97 +/- SEM 0.17 microgram/ml (HPLC) and 1.08 +/- 0.19 microgram/ml (microbiological assay) (NS). The respective mean urinary concentrations in the first 6-hour sample were 267 +/- 74 micrograms/ml and 241 +/- 58 micrograms/ml (NS). In bile, however, the microbiological assay gave higher values than HPLC:average peak concentrations of 10.3 +/- 3.4 micrograms/ml and 7.5 +/- 2.8 micrograms/ml (p less than 0.02) respectively, reached during the 2nd hour after drug administration, and mean total 24-hour biliary ciprofloxacin output of 2167 +/- 288 micrograms and 1587 +/- 222 micrograms (p less than 0.01) respectively. This may point to hepatic transformation of ciprofloxacin to more active metabolite(s) than the parent compound. The significantly higher concentrations of ciprofloxacin in bile than in serum exceeded the minimum inhibitory concentration for organisms usually responsible for biliary infections. These infections may, therefore, be favorably affected by ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158073

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  7 in total

Review 1.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

2.  Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial.

Authors:  Urte Zurbuchen; Joerg-P Ritz; Kai S Lehmann; Joern Groene; Majid Heidari; Heinz J Buhr; Christoph-T Germer
Journal:  Langenbecks Arch Surg       Date:  2007-12-18       Impact factor: 3.445

Review 3.  Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

Review 4.  Pharmacokinetics of ciprofloxacin.

Authors:  T Bergan; A Dalhoff; R Rohwedder
Journal:  Infection       Date:  1988       Impact factor: 3.553

5.  Biliary excretion of olsalazine sodium in humans.

Authors:  M Ryde; S Gustavsson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

6.  Transintestinal elimination of ciprofloxacin in humans--concomitant assessment of its metabolites in serum, ileum and colon.

Authors:  B Viell; B Krause; K H Vestweber; S Schaaf; H Scholl
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

7.  Pharmacokinetics: metabolism and renal excretion of quinolones in man.

Authors:  T B Vree; W J Wijnands; P J Guelen; A M Baars; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1986-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.